Dose escalation study of targeted alpha therapy with [225Ac]Ac-DOTA-substance P in recurrence glioblastoma - safety and efficacy.
Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska...
https://pubmed.ncbi.nlm.nih.gov/33860346/Actively Recruiting
Led by Medical University of Warsaw · Updated on 2026-04-06
35
Participants Needed
2
Research Sites
52 weeks
Total Duration
Brain tumors make up a small but significant portion of all cancers and are responsible for a notable percentage of cancer-related deaths. Gliomas, especially high-grade types like WHO grade 3 and 4, are common and challenging to treat due to their aggressive and infiltrative nature. Current treatments include surgery, radiotherapy, and chemotherapy, but survival rates remain low, highlighting the need for new approaches such as targeted therapies using neuropeptides labeled with alpha emitters. This study evaluates the safety and effectiveness of a local targeted therapy using the alpha emitter 225AcAc-DOTA-SP in patients with newly diagnosed high-grade gliomas after standard treatment. Participants will receive up to six cycles of this therapy administered directly to the tumor or resection cavity via a catheter placed during surgery. The treatment involves careful preparation, imaging, and monitoring, with hospitalization typically lasting about three days per cycle. Follow-up includes regular MRI scans and clinical assessments to track disease progression and side effects. Participants will undergo extensive evaluations including neurological exams, blood and urine tests, and imaging studies before, during, and after treatment. Researchers will measure progression-free survival and overall survival as primary outcomes, while closely monitoring safety and any adverse events. The study lasts approximately three years, with ongoing follow-up for patients who remain alive. Biological samples collected during surgery will be analyzed for genetic and pathological information, and all patient data will be anonymized to protect privacy.
CONDITIONS
Local, Targeted Therapy With Alpha Emitter [225Ac]Ac-DOTA-SP (TAT) In Newly Diagnosed Glioma (WHO G3-G4)
P
Przemysław Kunert, Professor MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Medical University of Warsaw
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Several days
Participants undergo tumor resection or biopsy and placement of up to three catheters for local treatment. This procedure requires several days of hospitalization.
Hospitalization for several days
Duration - Up to 4 cycles, timing varies per participant
Participants receive up to four cycles of local targeted therapy with alpha emitter [225Ac]Ac-DOTA-SP administered through the catheters. Treatment begins no earlier than 2 months after completion of radiotherapy.
Hospitalization for about 3 days per cycle with monitoring visits before each cycle and follow-up visits 2-4 weeks after each treatment
Duration - Up to 3 years or until death
Participants are monitored every 2 months during the first 18 months, then every 3 months or more frequently as needed, with MRI scans and clinical assessments to evaluate treatment efficacy and safety.
Regular visits every 2 months for 18 months, then every 3 months or as needed
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Have more questions? Get in touch with our team for quick support
Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska...
https://pubmed.ncbi.nlm.nih.gov/33860346/A Hilario, A Ramos, A Perez-Nuñez...
https://pubmed.ncbi.nlm.nih.gov/22207304/Leszek Królicki, Frank Bruchertseifer, Jolanta Kunikowska...
https://pubmed.ncbi.nlm.nih.gov/30498897/Eva Syková, Charles Nicholson
https://pubmed.ncbi.nlm.nih.gov/18923183/Dominik Cordier, Flavio Forrer, Stefan Kneifel...
https://pubmed.ncbi.nlm.nih.gov/20217458/Leszek Królicki, Jolanta Kunikowska, Frank Bruchertseifer...
https://pubmed.ncbi.nlm.nih.gov/36854309/D Cordier, F Forrer, F Bruchertseifer...
https://pubmed.ncbi.nlm.nih.gov/20157707/Medical University of Warsaw
Lead Sponsor